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An increased level of interleukin-6 (IL-6) in epithelial ovarian cancer (EOC) is correlated with a worse prognosis. IL-6
stimulates tumor-growth and inflammation. We investigated the intricate interaction between the IL-6 signaling
pathway and tumor-infiltrating myeloid cells (TIMs) to determine their prognostic impact in EOC. 160 EOC samples were
analyzed for the expression of IL-6, its receptor (IL-6R) and downstream signaling via pSTAT3 by immunohistochemistry.
Triple color immunofluorescence confocal microscopy was used to identify myeloid cell populations by CD14, CD33,
and CD163. The relationship between these markers, tumor-infiltrating immune cells, clinical-pathological
characteristics and survival was investigated. EOC displayed a dense infiltration with myeloid cells, in particular of the
CD163C type. The distribution pattern of all myeloid subtypes was comparable among the different histological
subtypes. Analysis of the tumor cells revealed a high expression of IL-6R in 15% and of IL-6 in 23% of patients.
Interestingly, tumors expressing IL-6 or IL-6R formed two different groups. Tumors with a high expression of IL-6R
displayed low mature myeloid cell infiltration and a longer disease-specific survival (DSS), especially in late stage
tumors. High expression of IL-6R was an independent prognostic factor for survival by multivariate analyses (hazard
ratio D 0.474, p D 0.011). In contrast, tumors with high epithelial IL-6 expression displayed a dense infiltration of mature
myeloid cells and were correlated with a shorter DSS. Furthermore, in densely CD8C T-cell infiltrated tumors, the ratio
between these lymphoid cells and CD163C myeloid cells was predictive for survival. Thus, IL-6 and IL-6R are opposite
markers for myeloid cell infiltration and survival.
Introduction
EOC remains a silent killer among women. Since most
patients are asymptomatic until the disease has metastasized,
two-thirds are diagnosed with advanced stage disease. Conven-
tional treatment (surgery combined with chemotherapy) results
are poor; 75% of the patients with advanced disease develop
recurrences, causing approximately 60–80% of patients to die
within 5 y of initial diagnosis.1-3 EOC consists of distinct histo-
logical subtypes. The most common subtype is serous carcinoma
which accounts for about 70% of EOC. Other subtypes are
endometrioid, mucinous and clear cell, of which the latter is asso-
ciated with a worse prognosis than all the other subtypes.4,5
EOC are infiltrated by a variety of immune cells.6-10 There are
strong correlations between the number and type of tumor-infiltrat-
ing lymphocytes (TILs) and a favorable clinical outcome.9,10 The
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spontaneous tumor-specific immune response, however, is weak and
counteracted by local immunosuppressive cells, like regulatory T
cells (T regs), preventing the infiltration or function of immune
effector cells. In addition to TILs, TIMs are present in EOC.
Tumor-associated macrophages (TAMs) and myeloid-derived sup-
pressor cells (MDSCs) originate from myeloid precursors in the
blood and undergo specific differentiation depending on cues in the
local tumor microenvironment. They can roughly be divided into
two distinct polarization states: the classically activated type 1 mac-
rophages (M1), which are tumoricidal and produce interleukin-12
(IL-12), as well as the alternative activated type 2 macrophages
(M2), which produce IL-10 and sabotage antitumor immunity. The
presence of M2 macrophages in ovarian tumors is correlated with
poor prognosis.11,12 MDSCs are a heterogeneous population of cells
that expand during cancer progression and have a remarkable ability
to suppress T-cell responses, albeit that their mode of action is differ-
ent from T regs.13
IL-6 is a major mediator of cancer-related inflammation by
stimulating inflammatory cytokine production, tumor growth,
tumor angiogenesis, and tumor macrophage infiltration in ovar-
ian cancer.14-17 Notably, the differentiation of both M2 macro-
phages and MDSCs can be mediated by IL-6.13,16,18 However,
the intricate interactions between IL-6 and tumor infiltration by
myeloid cells in ovarian cancer are not well understood.
Aiming to elucidate these interactions, we studied the expres-
sion of IL-6, IL-6 receptor (IL-6R) and phosphorylated signal
transducer and activator of transcription 3 (pSTAT3), important
mediators in the IL-6 signaling pathway, as well as the number
and type of infiltrating myeloid cells present in EOC. We deter-
mined the relationship between these markers, and their prognos-
tic or therapeutic impact in a unique cohort of EOC.9
Here, we demonstrate that the expression of IL-6 and its
receptor are opposite markers for survival and infiltration with
mature myeloid cells in ovarian cancer.
Results
Patient characteristics
Sufficient formalin-fixed paraffin embedded tumor tissue was
available from 160 ovarian cancer patients. Clinicopathological
characteristics of patients are summarized in Table 1. Half of the
patients presented with serous histology and/or high grade disease.
The majority of patients presented with late stage (FIGO stage III,
IV) disease. The median DSS was 51.0 mo (95% CI 32.9–69.1,
estimated 5-y DSS rate 46.1%). Of the patients treated with che-
motherapeutics, 77.5% received a platinum-based regimen of
whom 59.4% received this chemotherapeutic drug combined with
taxane. However, 24 patients did not receive chemotherapy, as 15
patients presented with FIGO stage I and the remaining patients
were either unfit or unwilling to receive chemotherapy.
Expression of markers of the IL-6 signaling pathway
First we evaluated the expression of IL-6, the IL-6R, and
pSTAT3 in EOC within the tumor epithelium and stroma
(Table 2A). Representative staining patterns of the markers are
depicted in Fig. 1. IL-6 expression was found in the tumor epithe-
lium of 23.0% of patients, while 46.1% of the patients showed stro-
mal expression. Expression of IL-6 in tumor epithelium was not
correlated with stromal expression of IL-6 (Table 2B). The IL-6R
was very abundant on the tumor epithelium of the patients in this
cohort with medium expression in 69.6% and high expression in
15.2% of all patients. Stromal expression of IL-6R was often absent
or weak (87.1%), however, when present (13%), it was positively
correlated with the expression of IL-6R on tumor epithelium (p <
0.001; Table 2B). There was no correlation between the expression
of IL-6 and the expression of IL-6R within the tumor epithelium or
stroma. The expression of pSTAT3 in tumor cells was found in
20% of the tumors, which was lower than the medium and high
expression of IL-6R in tumor epithelium. Statistical analyses
revealed that the expression patterns of pSTAT3 and the different
markers did not correlate to one another.
Markers of the IL-6-signaling pathway in different EOC
subtypes and disease stages
The entire cohort analyzed for the markers of the IL-6 signal-
ing pathway comprises a number of different histological
Table 1. Clinicopathological characteristics and survival data of the 160
patients included in TMA analysis
N (%)
Age (years)
Mean (SD) 57.99 (12.768)
DSS (months)
Median (95% CI) 51.0 (32.9–69.1)
FIGO stage
Stage I 41 (25.6%)
Stage II 13 (8.1%)
Stage III 83 (51.9%)





Clear cell 11 (6.9%)
Adenocarcinoma 7 (4.4%)
Mixed tumors 12 (7.5%)
Other 6 (3.7%)
Tumor grade
Grade I 25 (15.6%)
Grade II 52 (32.5%)








No chemotherapy 24 (15.0%)
Platinum-containing 29 (18.1%)
Platinum and taxane containing 95 (59.4%)
Other regimen 6 (3.8%)
Unknown 6 (3.8%)
DSS D disease-specific survival; FIGO D International Federation of Gynecol-
ogy and Obstetrics.
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epithelial ovarian tumor types (Table 1). In order to analyze sub-
type-specific associations, differences in expression of these
markers were examined. A high expression of IL-6R was more
frequently found in mucinous and endometrioid subtypes than
in tumors with serous histology (p D 0.032) (Table 2A). How-
ever, the expression levels of IL-6 did not differ between the dif-
ferent subtypes. Furthermore, we determined whether expression
varied between early (FIGO I/II) and late (FIGO III/IV) FIGO
stages. Early stage disease showed relatively more high epithelial
expression of the IL-6R (p D 0.035), which is in line with the
fact that the great majority of the early stage tumors were among
the mucinous and endometrioid tumors (Table S1). Late stage
tumors displayed increased levels of stromal IL-6 expression (p D
0.035) (Table 2A).
Infiltration of myeloid cell populations
In order to evaluate the presence of myeloid cells in EOC, we
quantified tumor tissues for macrophages (CD14), their matura-
tion status (CD33) and their polarization (M2; CD163) (Fig. 1).
CD14 is a specific monocyte/macrophage marker, although it
can also be found on subsets of dendritic cells.26 CD33 is
expressed on non-terminally differentiated myeloid cells27 and
CD163 is linked to macrophage anti-inflammatory functions.28-
30 The cellular distribution of these myeloid cell populations in
tumor epithelium and stroma is depicted in Table 2C. In
general, tumors displayed a suppressive microenvironment as
indicated by the high numbers of CD163-positive cells present.
The stroma was most densely infiltrated with myeloid cells. The
most abundant cell populations were CD14CCD33¡CD163C,
CD14CCD33CCD163C, and CD14¡CD33¡CD163C, both
in tumor and in stroma.
There was a correlation between the density of the different cell
types that infiltrated the tumor epithelium and the stroma (p <
0.001) in that having a large number of a certain cell type was associ-
ated with high numbers of other cell types infiltrating the tumor
(Table S2). Importantly, the distribution of the different subtypes
of myeloid cells followed the same distribution pattern for serous,
mucinous and endometrioid tumors. There were no overt differen-
ces in the number of infiltrating myeloid cells, except that intraepi-
thelial CD14CCD33CCD163C cells were virtually not present in
the mucinous subtype when compared to serous and endometrioid
tumors (p D 0.021). The same trend was observed for
CD14¡CD33CCD163C cells (pD 0.063). Furthermore, division
of the patients on the basis of early and late stage disease revealed a
trend for more stromal infiltration with CD14¡CD33CCD163C
cells in early stage cancer (p D 0.063). Thus the distribution and
number of all myeloid cell populations were grossly comparable
among the different histological subtypes and among early or late
stage tumors. Therefore, subsequent analyses on myeloid cells were
performed using the entire cohort as one group.
Table 2A. Expression patterns of IL-6, IL-6R, and pSTAT3 in epithelial tumor tissue and stroma, subdivided by stage and tumor type





















17 (15.2%) 78 (69.6%) 17 (15.2%) 4 (11.1%) 22 (61.1%) 10 (27.8%) 13 (17.1%) 56 (73.7%) 7 (9.2%) 0.035
IL-6R expression in
stroma
81 (87.1%) 10 (10.8%) 2 (2.2%) 27 (87.1%) 3 (9.7%) 1 (3.2%) 54 (88.5%) 6 (9.8%) 1 (1.6%) 0.885
IL-6 expression in
stroma
48 (53.9%) 35 (39.3%) 6 (6.7%) 19 (73.1%) 7 (12.7%) 0 (0.0%) 28 (45.2%) 28 (45.2%) 6 (9.7%) 0.035
Negative Positive Negative Positive Negative Positive
IL-6 expression in tumor
epithelium
89 (77%) 26 (23%) 31 (88.6%) 4 (11.4%) 58 (72.5%) 22 (27.5%) 0.058
pSTAT3 expression in
tumor
81 (80%) 20 (20%) 22 (81.5%) 5 (18.5%) 59 (79.7%) 15 (20.3%) 0.845





















10 (16.4%) 45 (73.8%) 6 (9.8%) 1 (9.1%) 5 (45.5%) 5 (45.5%) 3 (15.8%) 10 (52.6%) 6 (31.6%) 0.032
IL-6R expression in
stroma
37 (80.4%) 7 (15.2%) 2 (4.3%) 13 (100%) 0 (0.0%) 0 (0.0%) 8 (88.9%) 1 (11.1%) 0 (0.0%) 0.489
IL-6 expression in
stroma
24 (48.0%) 22 (44.0%) 4 (8.0%) 6 (66.7%) 2 (22.2%) 1 (11.1%) 4 (57.1%) 3 (42.9%) 0 (0.0%) 0.709
Negative Positive Negative Positive Negative Positive
IL-6 expression in tumor
epithelium
48 (76.2%) 15 (23.8%) 7 (63.6%) 4 (36.4%) 18 (94.7%) 1 (5.3%) 0.100
pSTAT3 expression in
tumor
45 (78.9%) 12 (21.1%) 6 (85.7%) 1 (14.3%) 15 (83.3%) 3 (16.7%) 0.860
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Tumor expressed IL-6R correlates with a less dense
infiltration of mature macrophages
The data from the whole cohort was used in our subsequent
analyses to determine the correlation between the expression
of IL-6 or pSTAT3 and the influx of myeloid cells, as the
expression of these two proteins was not related to a specific
histological subtype. Table 2B shows that high expression of
IL-6 in the tumor stroma was positively correlated with the
influx of CD14CCD33¡CD163¡ cells (p D 0.029) and
CD14CCD33¡CD163C cells (p D 0.011). We analyzed the
correlation between all mature (CD33-negative) myeloid cell
populations and found a positive correlation with IL-6 expression
in the tumor stroma (p D 0.007) (Table 2B). The expression of
IL-6 by the tumor epithelium was not significantly correlated
with the presence of myeloid cells. The expression of pSTAT3 by
tumor cells was related to a lower infiltration with
CD14¡CD33¡CD163C cells in tumor epithelium and stroma
(p D 0.043, p D 0.005 respectively).
In addition, we analyzed the expression of the IL-6R with
infiltration of different types of myeloid cells, taking into account
Figure 1. Representative staining patterns for (i) immunohistochemistry: (A) tumor core not expressing IL-6 (B) tumor positive for IL-6 (C) Magnification
of area with IL-6 producing cells (D) stroma expressing IL-6 (E) low expression of IL-6 receptor (F) medium expression IL-6 receptor (G) high expression
of IL-6 receptor (H) negative for pSTAT3 (I) pSTAT3 expressing tumor (J) Magnification quadrangle area of Figure 1I. And (ii) immunofluorescent staining
patterns: (K) merged image (L) Magnification quadrangle area of Fig. 1K (M) Black and white image (N) CD14 staining pattern (O) CD33 staining pattern
(P) CD163 staining pattern.
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the differences found in expression of the IL-6R in the different
histological subtypes. First we analyzed all subtypes together, and
found that a high expression of IL-6R by the tumor epithelium
was correlated with the infiltration of low numbers of different
types of intraepithelial macrophages, reflected by
CD14CCD33¡CD163¡, CD14CCD33¡CD163C and
CD14CCD33CCD163C (p < 0.001, p D 0.014, p D 0.022
respectively) and low numbers of stromal
CD14CCD33¡CD163¡ and CD14CCD33CCD163C cells
(p D 0.022, p D 0.027 respectively, Table 2B). A high expression
of IL-6R in stroma was negatively correlated with intraepithelial
infiltration by mature macrophages CD14CCD33¡CD163C (p
D 0.018), but was positively correlated with a dense influx of
immature myeloid cell populations represented by
CD14¡CD33CCD163¡ (p D 0.004). This same pattern was
seen in the stroma (Table 2B).
Then we analyzed the different histological subtypes by
comparing the number of the different stromal or intraepi-
thelial myeloid cells in tumors with low or no expression of
IL-6R vs. the tumors with a high expression of IL-6R. The
tumors of serous origin with high expression of IL-6R dis-
played a lower infiltration with intraepithelial and stromal
CD14CCD33¡CD163¡ cells, CD14CCD33¡CD163C
cells and CD14CCD33CCD163C cells when compared to
serous tumors with no or low IL-6R expression (Table S4).
The number of patients with a tumor of mucinous or endo-
metrioid origin stained for all markers was much lower than
the number of serous tumors, however, clearly the tumors with
a low IL-6R expression displayed high numbers of stromal
CD14CCD33-CD163C cells and CD14CCD33CCD163C cells,
while these numbers were strongly reduced in tumors with high IL-
6R expression (Table S4). Finally, late stage tumors with high
expression of IL-6R were also infiltrated by less intraepithelial and
stromal CD14CCD33¡CD163¡, CD14CCD33¡CD163C,
and CD14CCD33C CD163C cells as compared to their counter-
parts with a low expression of IL-6R (Table S4).
Then, the correlation between all mature (CD33-negative)
intraepithelial myeloid cell populations and IL-6R expression of
the tumor was analyzed. This confirmed that a dense infiltration
with mature intraepithelial myeloid cells was specifically detected
Table 2B. p-values of correlation markers of IL-6 signaling pathway with myeloid cell populations
IL-6R in tumor IL-6R in stroma pSTAT3 in tumor IL-6 in tumor IL-6 in stroma
Tumor epithelium
CD14CCD33¡CD163- ¡0.000 ¡0.170 ¡0.477 ¡0.590 0.029
CD14CCD33CCD163¡ ¡0.354 0.369 0.843 0.542 ¡0.474
CD14CCD33¡CD163C ¡0.014 ¡0.018 ¡0.735 0.192 0.011
CD14CCD33CCD163C ¡0.022 0.206 0.152 0.391 0.853
CD14¡CD33CCD163¡ ¡0.217 0.004 0.755 ¡0.872 0.654
CD14¡CD33CCD163C ¡0.256 0.065 0.729 ¡0.675 0.719
CD14¡CD33¡CD163C ¡0.079 ¡0.923 ¡0.043 0.449 0.120
IL¡6R 0.000 ¡0.820 0.335 ¡0.309
pSTAT3 0.820 0.869 0.990 ¡0.953
IL¡6 0.335 0.698 0.990 ¡0.230
Stroma
CD14CCD33¡CD163¡ ¡0.022 0.844 ¡0.119 ¡0.356 0.486
CD14CCD33CCD163¡ ¡0.357 ¡0.581 ¡0.256 ¡0.439 0.658
CD14CCD33¡CD163C ¡0.084 ¡0.523 ¡0.248 0.552 0.750
CD14CCD33CCD163C ¡0.027 ¡0.832 ¡0.985 0.903 0.954
CD14¡CD33CCD163¡ 0.817 0.048 ¡0.857 0.189 ¡0.895
CD14¡CD33CCD163C ¡0.288 0.226 0.752 ¡0.577 0.725
CD14¡CD33¡CD163C ¡0.577 0.144 ¡0.005 ¡0.572 ¡0.909
IL¡6R 0.000 0.869 0.698 ¡0.466
IL¡6 ¡0.309 ¡0.230 ¡0.953 0.332
Tumor epithelium
CD14CCD163¡ ¡0.081 ¡0.626 0.601 0.626 0.273
CD14CCD163C ¡0.023 ¡0.437 ¡0.797 0.684 0.162
CD14¡CD163C ¡0.265 0.505 ¡0.429 0.831 0.282
CD33C ¡0.096 0.048 0.568 ¡0.756 ¡0.928
CD33¡ ¡0.003 ¡0.178 ¡0.317 0.280 0.007
Stroma
CD14CCD163¡ ¡0.044 ¡0.633 0.497 ¡0.118 ¡0.549
CD14CCD163C ¡.012 ¡0.880 ¡0.342 ¡0.498 ¡0.499
CD14¡CD163C ¡0.614 0.136 ¡0.737 ¡0.317 ¡0.873
CD33C ¡0.088 0.733 ¡0.795 0.370 ¡0.756
CD33¡ ¡.161 ¡.568 ¡.412 ¡.636 ¡.034
1Different myeloid subsets were identified based on the expression of CD14, CD33, and CD163.
2p-values are given, bold signifies values that were considered a significant correlation if p < 0.05. – reflects negative correlation.
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in tumors with low/no IL-6R expression while their intraepithe-
lial numbers were low in tumors with a strong IL-6R expression
(p D 0.003; Table 2B). Divided per stage, more mature myeloid
cells (CD33¡) were seen in late stage patients (p D 0.013, data
not shown).
Univariate analysis of disease-specific survival
The influence of each marker on DSS was determined by con-
structing Kaplan–Meier curves, and differences between groups
were compared by Log Rank test. We found that epithelial IL-6
expression was correlated with a shorter DSS (p D 0.034). Inter-
estingly, a longer DSS (p D 0.010) was seen in patients having a
high expression of the IL-6R on tumor epithelium (Fig. 2). Since
early stage disease had relatively higher expression of the IL-6R,
the Kaplan–Meier analysis was also split into early and late stage
disease. This revealed that the survival difference was only seen in
late stage disease patients (p D 0.045; Fig. 2). There was no sur-
vival difference found between the different histological subtypes.
Further, DSS survival of patients was shorter if patients had a rel-
atively high infiltration with CD33¡ cells in tumor epithelium
(p D 0.017; Fig. 2). Here, no survival differences were observed
based on stage or histological subtype. Other markers were not
significantly correlated with DSS in univariate analysis.
Multivariate analysis
Variables that were significantly associated with DSS in the
univariate analyses were entered into a Cox proportional hazards
model. The model was adjusted for well-known prognostic
parameters and stratified for type of chemotherapy (Table 3). In
this model, IL-6 expression in tumor epithelium was not an inde-
pendent prognostic marker for survival (p D 0.851; HR D 0.940;
95% CI 0.491–1.797). Also CD33- infiltration did not show to
be an independent prognostic factor (p D 0.694; HR D 0.998;
95% CI 0.991–1.006). High IL-6R expression in tumor epithe-
lium, however, was correlated with early stage disease (p D
0.035), low grade tumors (p < 0.001; data not shown) and non-
serous tumors (p D 0.032; Table 2A). Importantly, in the multi-
variate analysis including these parameters, IL-6R expression in
tumor epithelium was considered to be an independent prognos-
tic marker. High expression was associated with a longer DSS,
represented by a hazard ratio of 0.474 (p D 0.011; 95% CI
0.268–0.841).
Unsupervised hierarchal clustering based on immune
parameters
Previously we reported the infiltration of these tumors by
T cells.9 To gain a better insight into the immunological composi-
tion of EOC, we constructed a heatmap (Fig. 3A) containing 76
patients of which data from all previously established lymphoid
parameters, our current data on myeloid cell populations, and on
the markers of the IL-6 signaling pathway were available. Unsu-
pervised clustering divided the patients into two major groups (A
and B) that were both subdivided into two groups (A1 and A2,
B1 and B2), which could be further subdivided into six smaller
groups (A1, A2I, A2II, B1, B2I, and B2II). The Kaplan–Meier
analysis of the six subgroups is shown in Fig. 3B. A significant
survival difference was found between groups B2I and B2II (p D
0.039), with the patients in group B2II displaying a shorter sur-
vival. Tumors in group B2II showed a dense infiltration of lym-
phoid (including FoxP3C cells) and myeloid cells. Group B2I on
the other hand comprised tumors from patients in which the infil-
trating myeloid cells were mostly of the CD163-negative subtype.
Furthermore, the tumors in this group displayed dense infiltration
with CD8C cells, but low numbers of infiltrating FoxP3Ccells.
These observations led us to hypothesize that the proportion
of CD8C T cells and tumor promoting CD163C myeloid cells
(CD8/CD163 ratio) is predictive for survival. Fig. 3C presents
the Kaplan–Meier analysis on the CD8/CD163 ratio in the
group of patients with high lymphocyte infiltration (CD8C infil-
tration above median). Indeed, this ratio was predictive for sur-
vival (p D 0.036) and this was independent of the stage of disease
(data not shown).
Discussion
We studied the composition of infiltrating myeloid cells and
the expression of important mediators in the IL-6 signaling path-
way in EOC. In general, ovarian tumors pose a hostile environ-
ment to immune effector cells, reflected by a dense infiltration
with suppressive CD163C types of myeloid cells as shown here
and by others.31,32 The most abundant intraepithelial and stro-
mal cell populations we found were CD14CCD33¡CD163C
cells, CD14CCD33CCD163C cells, and CD14¡CD33–
CD163C cells. Whereas the former two represent M2 macro-
phages, the latter population is likely to reflect immunosuppres-
sive dendritic cells (DCs) or DC-derived macrophages.30,33 As
ovarian cancer refers to five different histological subtypes with
distinct sites of origin, one can imagine that they have differences
in the immune composition as well. Here, however, we show
that the distribution pattern of all myeloid subtypes was compa-
rable and proportional in the analyzed histological subtypes, sug-
gesting that although EOC can originate from different cell types
their attraction and polarization of myeloid cells does not really
differ. There were no particular myeloid subpopulations directly
correlated with DSS.
The expression of the IL-6R was most often seen in early
stage, low grade, and non-serous histology, but was also found
among serous tumors and late stage cancers. A high expression of
the IL-6R on EOC cells was associated with a significantly longer
DSS, an effect that was specifically seen in late stage disease and
not among early stage patients who all did very well (Fig. 2).
Importantly, the expression of IL-6R was an independent prog-
nostic marker for an improved DSS in a multivariate analysis in
which stage, grade, and histology were taken into account (p D
0.011; 95% CI 0.268–0.841).
Interestingly, tumors with a high expression of the IL-6R dis-
played a general lower number of intraepithelial and stromal
myeloid cells than those with low or no IL-6R expression. Espe-
cially the number of mature (CD33-) myeloid cells was lower in
tumors with high IL-6R expression. This suggests that the local
microenvironment of tumors with a high IL-6R expression is less
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suppressive. Indeed, we
observed a correlation between
low infiltration with mature
(CD33-) myeloid cells and
longer survival. Although IL-
6R expression is positively cor-
related with an influx of imma-
ture CD33C cells, these are
likely to reflect the previously
identified inflammatory aner-
gic macrophages that, as such,
will not contribute to immune
suppression.34 In one other
study of IL-6R expression in
ovarian cancer tissue no corre-
lation was found between IL-
6R expression and survival.17
Here, the expression of IL-6R
was scored using a different
method and the survival was
plotted based on the median
expression. Thereby, the
patients with medium and
high expression of IL-6R were
mixed, whereas we found a dif-
ference in survival by plotting
on basis of high IL-6R
expression.
Our data suggest that the
tumors with no to low expres-
sion of IL-6R do not require
IL-6R receptor signaling for
their growth and that tumors
still expressing IL-6R depend
on IL-6 produced outside the
tumor cell. A possible explana-
tion for the lack of staining
could be that the more pro-
gressive tumors express a dif-
ferentially spliced isoform of
IL-6R that lacks the trans-
membrane35 and as such will
not be detected. However, we
envision that once tumors have
an autocrine production of IL-
6, and can provide IL-6 needed
for growth, signaling, and
immunosuppressive actions,
the receptor might be lost, and
tumors may become more
resistant.36,37 Our data corrob-
orate this hypothesis, since
tumor expression of IL-6 and
IL-6R are not correlated.
A high expression of IL-6
within the tumor is correlated
Figure 2. Kaplan–Meier survival analysis for disease-specific survival (DSS), differences between groups were
analyzed by Log Rank test. (A) IL-6 expression in tumor epithelium is a predictor of shorter survival (p D 0.034).
(B) High expression of the IL-6 receptor in tumor epithelium is associated with a longer DSS (p D 0.010). (C) IL-6R
expression analyzed for early and late stage disease. In early stage patients, no difference in DSS was detected
for the different expression groups (p D 0.239). In late stage patients, a high expression of the IL-6 receptor in
tumor epithelium is associated with a longer DSS (p D 0.045). (D) Patients having a low infiltration of CD33- cells
(lowest tertile) show an improved survival (p D 0.017) as compared to patients with a higher infiltration of these
cell types. (E) No survival differences were detected when CD33- infiltration was analyzed for DSS in early vs. late
stage disease patients.
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with a shorter DSS (p D 0.034), albeit that IL-6 expression was not
an independent prognostic factor. This observation sustains previ-
ous notions that the level of serum IL-6 in EOC patients correlates
with poor survival.38-40 Surprisingly, the myeloid cell infiltration of
tumors with high IL-6 expression was the opposite of that found in
tumors with high IL-6R expression. Tumors with high IL-6 expres-
sion displayed a dense infiltration with CD14CCD33¡CD163C
cells and CD14CCD33¡CD163C cells, specifically the mature
(CD33-) type of myeloid cells. Our observation that the
expression of IL-6 was correlated with the presence of
CD14CCD33¡CD163- cells, potentially reflecting recent infil-
trated monocytes or M1 macrophages,24 is somewhat counterintui-
tive. However, as the number of these tumor-infiltrating cells was
generally low when compared to other cancer types,24 and is
directly correlated to co-infiltration with much larger quantities of
suppressive CD33¡CD163C cells, this association is more likely
to reflect that in essence IL-6 expressing tumors induce a hostile
tumor immune environment. This scenario corresponds also with
our observations that IL-6 producing ovarian cancer cells can polar-
ize the differentiation of monocytes toward M2 macrophages.18 A
high level of IL-6 in the tumor microenvironment may attract and
differentiate macrophages into subtypes that in their turn produce
more IL-6, creating an immunosuppressive environment. Recently,
Reinartz et al.41 defined a subgroup of ovarian cancer patients with
a poor clinical outcome, these patients displayed a high CD163
expression and high IL-6 levels in ascites.
In order to obtain a better understanding of the immune com-
position of these tumors, we performed an unsupervised cluster-
ing on all known immune parameters and IL-6 pathway markers.
This revealed roughly two types of tumor environments with a
difference in survival (Fig. 3). We can distinguish (i) a tumor
rejecting environment (B2I) with a high infiltration of cytotoxic
CD8C T cells and fewer M2 macrophages and FoxP3C cells (T
regs), associated with a favorable clinical outcome and (ii) an
immunosuppressive environment (B2II), with high infiltration of
T regs and M2 macrophages, and a low infiltration of CD8C
cells, associated with a worse prognosis. Interestingly, in a recent
study it was shown that such a composition of the tumor infiltrat-
ing immune cells in ovarian cancer is related to tumor expression
of HOXA9.42 Previously, we and others have shown that the
CD8/T reg ratio was predictive for survival in EOC.9,38,43 The
constructed heatmap led us to hypothesize that in tumors highly
infiltrated with CD8C cells, the positive effect of CD8C T cells
may be counteracted by suppressive CD163C myeloid cells and
thus influence survival. Indeed, the CD8/CD163 ratio in highly
infiltrated tumors was a predictive marker for DSS (p D 0.036),
confirming the role of CD163C cells as an immunosuppressive
population and implying that patients may benefit from therapy
that either depletes M2 macrophages or switches polarization of
CD163C cells toward M1 macrophages.
In summary, we found that IL-6R expression on tumor cells is an
independent predictive factor for improved outcome and is associ-
ated with a low infiltration of mature myeloid cells. Furthermore,
we showed that IL-6 is associated with a high density of mature mye-
loid cells and is correlated with a worse prognosis. In addition, a high
density ofM2myeloid cells displayed a negative impact on CD8C T
cells; in patients with a high lymphocyte infiltration, the CD8/
CD163 ratio is a positive predictor of survival. Based on these data
we can distinguish two types of tumors based on IL-6, IL-6R, and
immune infiltration. The first group of patients has tumors with a
high expression of IL-6R and a low infiltration by mature myeloid
cells. These patients have a good survival, suggesting that determina-
tion of IL-6R expression might be useful as a prognostic marker.
The second group consists of patients of which tumors do not dis-
play the IL-6R, but have a high expression of IL-6, and are densely
infiltrated with mature CD163C myeloid cells. These patients have
a worse prognosis and, potentially, blocking of the IL-6R may pre-




Since 1985, the Department of Gynecological Oncology of
the University Medical Centre Groningen (UMCG) prospec-
tively stores all clinicopathologic and follow-up data of malignant
EOC patients in a digital database. Primary treatment of all
Table 3.Multivariate Cox regression analyses of disease-specific survival in ovarian cancer patients
IL-6 in tumor epithelium IL-6R in tumor epithelium CD33- in tumor epithelium
HR 95% CI p-value HR 95% CI p-value HR 95% CI p-value
Age 58 years 0.655 0.334–1.286 0.219 0.578 0.276–1.212 0.147 0.738 0.346–1.571 0.430
Grade III/Undifferentiated 0.933 0.485–0.1.796 0.835 0.606 0.293–1.255 0.178 0.674 0.297–1.530 0.346
Non-serous tumor 0.428 0.199–0.918 0.029 0.460 0.204–1.040 0.062 0.376 0.147–0.961 0.041
FIGO stage III/IV 20.862 2.538–171.496 0.005 25.096 2.878–218.865 0.004 20.281 2.316–177.630 0.007
Residual tumor >2cm 2.528 1.298–4.924 0.006 3.847 1.776–8.333 0.001 3.699 1.569–8.718 0.003
IL-6 expression in tumor epithelium 0.940 0.491–1.797 0.851
IL-6R expression in tumor epithelium 0.474 0.268–0.841 0.011
CD33- infiltration in tumor epithelium 0.998 0.991–1.006 0.694
Analyses preformed stratified for type of chemotherapy; FIGO: International Federation of Gynecology and Obstetrics; HR: hazard ratio;
CI: confidence interval; bold signifies p < 0.05.
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Figure 3. (A) A heatmap was created by unsupervised hierarchal clustering of patients based on all known immunological parameters. Included were
lymphoid and myeloid cell populations and markers of the IL-6 signaling pathway. The changes from the lowest to highest tertile are reflected by a
darker color, white boxes are missing data. On the X-axis the 76 included patients are depicted, and on the Y-axis all immune parameters are indicated.
Each column represents the immune profile of one patient. Brackets to the left and along the top indicate the unsupervised clustering. (B) Kaplan–Meier
analysis for the disease-specific survival of the six subgroups as determined by clustering analysis. A significant survival difference was found between
groups B2I and B2II (p D 0.039). (C) Kaplan–Meier survival analysis for disease-specific survival of CD8/CD163 ratio lowest tertile vs. all other patients in
patients with a high lymphocyte infiltrate (above median). Patients with a low ratio had significant shorter DSS (p D 0.034). Differences were analyzed by
Log Rank test.
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patients consisted of surgery, followed (when possible) by adju-
vant chemotherapeutic treatment. Since 1995, platinum-based
chemotherapy was supplemented with taxanes. Patients were sur-
gically staged according to International Federation of Gynecol-
ogy and Obstetrics (FIGO) classification.19 Optimal and
suboptimal debulking was defined as the largest residual tumor
lesions having a diameter of, respectively, <2 cm or 2 cm. His-
tology of all tumors was determined according to World Health
Organization criteria.20 Follow-up was updated in July 2009.
For the present study, relevant data from our digital database of
all patients were transferred into a separate anonymous database,
in which patient identity was protected by unique patient codes.
According to Dutch law, no approval from our institutional
review board was needed.
Tissue Micro-Arrays
Tumor samples from 361 patients were collected on a tissue
micro-array (TMA). This TMA contained primary ovarian
tumor tissue of 270 patients obtained before chemotherapeutic
treatment. Patients with borderline or non-epithelial tumors
were excluded. For this study, a cohort with the most recently
treated patients (N D 160) was selected for analysis. The TMAs
were constructed as previously described.9,21,22 In brief, four
representative cores with a diameter of 0.6 mm were taken out
of paraffin-embedded tissue blocks using a tissue microarrayer
(Beecher Instruments, Silver Spring, MD, USA) and were
placed on a recipient paraffin block. From each TMA block,
sections of 4 mm were cut and applied to APES-coated slides.
The presence of tumor in the arrayed samples was confirmed by
H&E staining.
Immunohistochemical staining
TMA sections were deparaffinized and rehydrated using
xylene and graded concentrations of ethanol. Heat-induced
antigen retrieval was performed in citrate buffer (10 mM cit-
rate, pH 6.0). Endogenous peroxidase was blocked in a 0.3%
H2O2 solution, after which sections were incubated with pri-
mary antibodies overnight at 4C; rabbit polyclonal IL-6
antibody (1:400, Abcam), rabbit polyclonal to IL-6Ra
(1:800, Santa Cruz Biotechnology), and rabbit monoclonal
pSTAT3 antibody (1:150, Cell Signaling Technology, clone
Tyr705). The antibodies were detected using HRP-labeled
secondary (goat anti-rabbit) and tertiary (rabbit anti-goat)
antibodies for 30 min at RT (1:100, DAKO,), and visualized
with 3,3-diaminobenzidine. Hematoxylin was used for
counterstaining.
Scoring
All staining patterns were scored independently by two
observers, who had no prior knowledge of clinicopathological
information. To achieve good concordance with whole tissue
slides, minimally two cores containing at least 20% tumor epi-
thelium had to be present on the TMA for a sample to be selected
for further analysis.21 IL-6 expression in stroma and IL-6R stain-
ing were scored according to the method of Ruiter et al.23 The
intensity of the staining was scored as 0 (absent), 1 (weak), 2
(positive), or 3 (strong expression). The percentage of positive
tumor cells was grouped as 0 (0%), 1 (1–5%), 2 (5–25%), 3
(25–50%), 4 (50–75%), and 5 (75–100%). The sum of these
two scores was divided by the number of evaluated cores per
tumor, which was subsequently grouped into no/weak expression
(0–2), medium expression (3–6), and high expression (7–8). IL-
6R expression in stroma was scored in four intensity categories:
none, weak, medium, or strong staining. Patients were categori-
cally defined as either having positive or negative expression for
IL-6 or pSTAT3 within the tumor epithelium, with the latter
localized to the nucleus.
Immunofluorescent staining
Characterization of TIM was carried out with triple immuno-
fluorescent staining as described previously.24 Briefly, after depar-
affinization and rehydration of the 4-mm tissue sections, heat-
mediated antigen retrieval with a 1 mmol/L EDTA solution (pH
9.0) was performed. A mixture containing primary antibodies
anti-CD33 (1:50, mouse-IgG2b, clone PWS44, Leica Microsys-
tems B.V.), anti-CD14 (1:100, mouse-IgG2a, clone 7, Leica
Microsystems B.V.) and anti-CD163 (1:400, mouse-IgG1,
Clone 10D6, Leica Microsystems B.V.) was applied to the tissue
sections overnight at room temperature. The next day, a mixture
of fluorescently labeled secondary antibodies (goat anti-mouse
IgG2b-Alexa Fluor 546, goat anti-mouse IgG2a-Alexa Fluor 488
and goat anti-mouse IgG1-Alexa Fluor 647; Molecular Probes)
was used to detect primary antibody binding. Images were cap-
tured with a confocal laser scanning microscope (Zeiss LSM 510)
in a multitrack setting. Epithelial tumor cell nests and stromal
areas were measured using the Zeiss LSM Image Examiner. Mye-
loid subsets were manually counted in all representative images
for either tumor epithelium, stroma, or both and were presented
as the number of cells per mm2.
Statistical analysis
Statistical analysis was performed using Statistical Package for
the Social Sciences [SPSS Statistics] 20 software package for Win-
dows (SPSS Inc.). For all tests, p-values <0.05 were considered
significant and all p-values were tested two-sided. DSS was
defined as the time period from date of surgery until death due
to ovarian cancer or last follow-up. DSS was calculated using the
Kaplan–Meier method. Survival differences between groups were
assessed using the Log Rank test. Variables that were significantly
associated with DSS in the univariate analyses were entered into
a multivariate analysis. For this purpose, Cox proportional haz-
ards models, stratified for type of chemotherapy, were used. The
x2 test was used to associate markers of the IL-6 pathway, mye-
loid cell populations, lymphoid cell populations, and clinico-
pathological parameters. Spearman’s correlation was applied to
calculate correlation between the myeloid cell populations. The
Mann Whitney U test with Bonferroni correction for
multiple comparisons was used to determine differences in infil-
tration of myeloid cells and IL-6R expression between patient
populations.
Unsupervised hierarchical clustering was performed as
described previously25 using complete-linkage and Euclidian
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distance in the function “heatmap” of the “stats” package in R.
(Development Core Team, a language and environment for sta-
tistical computing, reference index version 2.14.0. 2005. Foun-
dation for Statistical Computing, Vienna, Austria).
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